Aslan Pharmaceuticals Ltd. ADR Stock

$0.60

0.00%

Nasdaq, Fri, Dec 27 2024

ISIN

US04522R1014

Symbol

ASLN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Aslan Pharmaceuticals Ltd. ADR Stock price

$0.60

-85.80 99.31% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

+0.00 0.00%

ISIN

US04522R1014

Symbol

ASLN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$1.70m
Enterprise Value	$9.97m
P/E (TTM) P/E ratio	negative
EV/Sales (TTM) EV/Sales	0.83
P/S ratio (TTM) P/S ratio	0.14
P/B ratio (TTM) P/B ratio	negative
Revenue (TTM) Revenue	$12.00m
EBIT (operating result TTM) EBIT	$-34.92m
Cash position	$18.40m
EPS (TTM) EPS	$-15.94
P/E forward	negative
Short interest	1.46%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Aslan Pharmaceuticals Ltd. ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Aslan Pharmaceuticals Ltd. ADR:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Aslan Pharmaceuticals Ltd. ADR:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Aslan Pharmaceuticals Ltd. ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '24		+/- %
Revenue	12 12	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	13 13	11% 11% 105%
- Research and Development Expense	34 34	20% 20% 286%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-35 -35	35% 35% -291%
Net Profit	-35 -35	39% 39% -292%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Aslan Pharmaceuticals Ltd. ADR Stock News

Neutral

GlobeNewsWire

●

5 months ago

ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation

SAN MATEO, Calif. and SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that its Singapore-incorporated, sole operating subsidiary, ASLAN Pharmaceuticals Pte Ltd (“ASLAN SG”), has filed for voluntary liqu...

Neutral

GlobeNewsWire

●

6 months ago

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal

SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that on July 9, 2024, the Company was notified by the staff of the Listing Qualifications Department (the "Staff") of ...

Company Profile

Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002. The firm's portfolio focuses on validated growth pathways applied to new patient segments, novel immune checkpoints, and novel cancer metabolic pathways. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.

Head office	Cayman Islands
CEO	Carl Firth
Employees	35
Founded	2010
Website	www.aslanpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now